Mucolipidosis type III

Mucolipidosis type III (ML III), also known as pseudo-Hurler polydystrophy, is a rare inherited lysosomal storage disorder caused by a deficiency of the enzyme UDP-N-acetylglucosamine-1-phosphotransferase. This enzyme is essential for proper targeting of lysosomal enzymes to the lysosome; when it is deficient, lysosomal enzymes are mistakenly secreted outside the cell rather than being directed to lysosomes, leading to accumulation of undigested substrates within cells. ML III is considered a milder, later-onset form compared to mucolipidosis type II (I-cell disease). Two subtypes are recognized: ML III alpha/beta (caused by mutations in the GNPTAB gene) and ML III gamma (caused by mutations in the GNPTG gene). ML III primarily affects the skeletal system, joints, and connective tissues. Key clinical features include progressive joint stiffness and contractures, claw-hand deformity, short stature, scoliosis, hip dysplasia, and carpal tunnel syndrome. Coarsening of facial features may be present but is typically milder than in mucolipidosis type II. Cardiac valve disease (particularly aortic and mitral valve thickening) can develop over time. Corneal clouding may occur, and mild cognitive impairment is seen in some patients, though intelligence is often preserved or only mildly affected. Symptoms usually become apparent in early childhood, typically between ages 3 and 5 years, and progress slowly through adolescence and adulthood. Bone and joint complications, particularly destructive hip joint disease, are a major source of morbidity. There is currently no cure or disease-specific therapy for mucolipidosis type III. Management is supportive and multidisciplinary, focusing on orthopedic interventions (including physical therapy and surgical procedures such as hip replacement for severe joint disease), cardiac monitoring, ophthalmologic care, and pain management. Unlike some other lysosomal storage disorders, enzyme replacement therapy has not been developed for ML III. Bone marrow transplantation has been attempted in rare cases but is not standard of care. Life expectancy may be reduced depending on the severity of cardiac and respiratory complications, though many patients survive into adulthood.

Common questions about Mucolipidosis type III